BioSpace News Archive

InspireMD, Inc. today announced that it has promoted Andrea Tommasoli to Chief Operating Officer.

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, today announced pooled gait data from a world-renowned gait laboratory in Adelaide, Australia, which served as a study site for two studies of lead candidate XT-150 in patients with knee osteoarthritis (OA).

PaxMedica, Inc. today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical stage biotechnology company, today announced the launch of its Pet2DAO website in preparation for previously announced distribution of PDAO tokens to shareholders.

I-Mab today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

FORE Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead program, FORE8394, for the treatment of primary brain and central nervous system (CNS) malignancies.

InvisiShield Technologies Ltd. today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479.

QSAM Biosciences, Inc. is pleased to announce that it has been invited to provide updates on its clinical trial evaluating CycloSam® for the treatment of metastatic bone cancer at the Emerging Growth Conference on Wednesday, March 22, 2023, at 2:50 PM EST.

SurgVision, a high-tech company developing pioneering solutions for fluorescence-guided surgical and interventional oncology, part of the Bracco Group, announces that it has received 510(k) clearance from the U.S. Food and Drug Administration for the EXPLORER AIR® II for use with Pafolacianine (CYTALUX, On Target Laboratories Inc.) during intraoperative fluorescence imaging.